Lhasa Limited is thrilled to announce the launch of Kaptis!
Aligned with the recent finalisation of the ICH S1B(R1) guideline, Kaptis includes ICH S1 functionality. The ICH S1 functionality supports more efficient evaluation of compound carcinogenic potential and can be used to determine whether a full carcinogenicity animal study is necessary.
Lhasa has invested a significant amount of time into understanding this area, earlier this year forming an ICH S1 consortium. The consortium consists of several key industry partners, all with a common goal of supporting meeting ICH S1 in a faster and more cost-effective manner.
This launch of Kaptis means that for the first time, scientists around the world can use adverse outcome pathway (AOP) networks to perform carcinogenicity assessments, utilising transparent AOP knowledge developed by Lhasa, alongside proprietary assay data.
Kaptis can be used to answer the question, “Is my compound likely to be carcinogenic?”, with Kaptis ICH S1 reporting also designed to support consistent industry carcinogenicity assessments and ICH S1 regulatory submission.
"Kaptis is an important tool for the development and interpretation of Integrated Approaches to Testing and Assessment for carcinogenicity" – Carole Yauk, Professor and Canada Research Chair in Genomics and the Environment.
Ultimately the uptake of Kaptis will result in more transparent, faster and cheaper carcinogenicity assessments which also minimise the use of animal testing – resulting in more ethical and environmentally friendly assessments.
If you would like to learn more about how this innovative solution would improve your own ICH S1 carcinogenicity assessments, please get in touch or email us at hello@lhasalimited.org.